MDCK (Madin-Darby Canine Kidney) cell line for stably expressing human TMEM135 gene as well as construction method and application thereof
By stably expressing the human TMEM135 gene in the MDCK cell line, the endosomal escape of influenza A virus was promoted, the problem of inhibition of the release of viral genetic material was solved, the efficiency and quality of vaccines were improved, and the virus titer and genetics were enhanced. stability.
Patent Information
- Application Number
- CN202411230974.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-08
AI Technical Summary
The existing MDCK cell lines have an increase in membrane fusion energy barrier during the endosome escape of influenza A virus, resulting in inhibition of the release of viral genetic material, affecting vaccine production efficiency and quality.
Constructing an MDCK cell line that stably expresses the human TMEM135 gene. By amplifying the human TMEM135 gene and building a stable expression vector, it was co-transfected to 293T cells to produce packaged lentiviruses. Infected MDCK cells were screened for puromycin, which could accelerate the acquisition. MDCK cell lines transported by cholesterol in host cells promote endosomal escape of influenza A virus.
It improves the titer of influenza A virus in host cells, enhances the yield and genetic stability of the virus, simplifies the production process of influenza vaccines, and reduces the risk of virus mutation.
Smart Images

Figure CN118909954A_ABST
Abstract
Description
[0001] The invention belongs to the field of biotechnology, and particularly relates to an MDCK cell line stably expressing a human TMEM135 gene, and a construction method and application thereof. Background Art
[0002] Influenza A is a respiratory infectious disease caused by influenza A virus (IAV), which poses a serious threat to human life safety and the economic value of livestock and poultry. In order to quickly control and prevent the spread of the virus, an effective and safe vaccine has become the key. In recent years, the advantages of cell culture vaccine production have gradually become prominent, and its safety, economy and effectiveness have been significantly improved. Especially in the production of influenza vaccines, cell culture technology is expected to replace the traditional chicken embryo production method and become the mainstream trend in the future. Therefore, establishing a cell line with more efficient toxin production will not only help improve the yield and quality of the vaccine, but also provide strong technical support for the prevention and control of influenza viruses.
[0003] Influenza A virus (IAV) releases viral genetic material by adsorption, endocytosis and endosomal escape in host cells. The endosomal escape process of IAV requires the fusion of the viral envelope and the host endosomal membrane to release viral genetic material. Studies have shown that the accumulation of cholesterol in host cells can increase the energy barrier of IAV membrane fusion, thereby inhibiting the endosomal escape stage of IAV. In theory, constructing a cell line that promotes cholesterol transport can facilitate the membrane fusion of IAV and accelerate the release of viral genetic material, thereby increasing the yield of influenza A virus.
[0004] The remarkable advantage of MDCK as influenza virus amplification matrix is that it all shows high susceptibility to multiple influenza virus subtype strains, and the intracellular amplification rate is fast, and higher virus titer can be obtained. In addition, the proliferation rate of MDCK cells is fast, and the production cycle is short, which further improves the production efficiency of the vaccine. And the virus amplified through MDCK cells is not easy to mutate, and compared with the original virus strain, its genetic stability is higher. Compared with other production matrices (such as chicken embryo), MDCK cells provide a virus product closer to the original virus strain. These advantages make MDCK cells occupy an important position in influenza vaccine production, and provide new direction and potential for future vaccine research and development.
[0005] The TMEM (Transmembrane protein) family refers to a family of transmembrane proteins whose members have diverse transmembrane structures and functions on the cell membrane. Members of this family are involved in multiple biological processes such as cell signaling, apoptosis, cell adhesion, and intracellular transport. TMEM135 (Transmembrane protein 135) is a protein with five transmembrane domains, of which the four human TMEM135 isoforms are highly conserved among species and have a high degree of homology in mice, cattle, dogs, and zebrafish. Recent studies have shown that when TMEM135 is depleted, the intracellular cholesterol distribution becomes disordered, specifically manifested as the accumulation of cholesterol in lysosomes. Existing studies have also confirmed that TMEM135 plays an important role in the interaction between mitochondria and peroxisomes. After TMEM135 interacts with the kinase anchor protein AKAP1 on mitochondria, it activates the phosphorylation of the downstream mitochondrial fission factor DRP1, promotes mitochondrial fission, and enables the body to generate more heat. In general, TMEM135 plays an important role in cellular cholesterol transport and mitochondrial fusion and fission. Summary of the invention
[0006] In order to solve the above problems, the present invention provides an MDCK cell line stably expressing the human TMEM135 gene and its construction method and application. The present invention successfully constructs and screens a high-yield MDCK cell line suitable for the proliferation of influenza A virus, which contains the human TMEM135 gene, can accelerate the transport of cholesterol in host cells, promote the endosomal escape of influenza A virus, and increase the virus titer produced by influenza A virus after infecting host cells.
[0007] The technical solution of the present invention is:
[0008] A MDCK cell line stably expressing the human TMEM135 gene, named as canine kidney cell MDCK-homoTMEM135 Madin Darby Canine Kidney Cells, is deposited in the China Center for Type Culture Collection, and its culture collection number is: CCTCC NO: C2024260.
[0009] The nucleotide sequence of the human TMEM135 gene is shown in SEQ ID No.1.
[0010] The application of the MDCK cell line stably expressing the human TMEM135 gene in the proliferation of influenza A virus.
[0011] The method for constructing the MDCK cell line stably expressing the human TMEM135 gene comprises the following steps:
[0012] (A) Amplify the human TMEM135 gene and construct a stable expression vector;
[0013] (B) co-transfecting the stable expression vector described in step (A) with pxPAX2 and pMD2G plasmids into 293T cells, and incubating to produce packaged lentivirus;
[0014] (C) After infecting MDCK cells with the packaged lentivirus, puromycin drug screening was performed and culture was expanded to obtain the MDCK cell line stably expressing the human TMEM135 gene.
[0015] In step (A), the primer sequences for amplifying the human TMEM135 gene are shown in SEQ ID No. 2 and SEQ ID No. 3.
[0016] In step (A), the construction of the stable expression vector is specifically performed as follows:
[0017] The amplified human TMEM135 gene was connected to the vector fragment, and the resulting connection product was added to DH5α competent cells. After heat shock, it was added to the culture medium for culture, and monoclonal colonies were selected and plasmids were extracted.
[0018] The vector fragment is a vector fragment obtained after Phage plasmid digestion.
[0019] The heat shock is performed at 40-45° C. for 35-45 seconds; and the culture medium is LB culture medium.
[0020] The beneficial effects of the present invention are:
[0021] (1) The present invention provides an MDCK cell line stably expressing a human TMEM135 gene, wherein the cell line is a canine kidney cell MDCK-homoTMEM135, and its culture collection number is: CCTCCNO: C2024260. The MDCK cell line contains a human TMEM135 gene, which can accelerate the transport of cholesterol in host cells, promote the endosomal escape of influenza A virus, and increase the virus titer produced by influenza A virus after infecting host cells.
[0022] (2) The present invention provides a method for constructing an MDCK cell line that stably expresses the human TMEM135 gene, by first amplifying the human TMEM135 gene and constructing a stable expression vector, then co-transfecting the stable expression vector with pxPAX2 and pMD2G plasmids into 293T cells, and incubating to produce packaged lentivirus; finally, infecting MDCK cells with the packaged lentivirus, performing puromycin drug screening and expanding the culture, thereby obtaining the MDCK cell line that stably expresses the human TMEM135 gene. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0024] Figure 1 A diagram showing the identification result of the RT-PCR amplification of the human TMEM135 gene described in Example 1 of the present invention;
[0025] Figure 2 It shows the identification of MDCK-homoTMEM135 cell subclones obtained in Example 1 of the present invention;
[0026] Figure 3 The results of the MDCK-homoTMEM135 cell stability test obtained in Example 1 of the present invention are shown;
[0027] Figure 4a Shows the cholesterol fluorescence staining images in MDCK (control group) and MDCK-homoTMEM135 at different time periods in the cholesterol consumption experiment;
[0028] Figure 4b The fluorescence intensity of cholesterol staining in MDCK and MDCK-homoTMEM135 cells at different time periods is shown. *.P<0.05, **.P<0.01, ***.P<0.001;
[0029] Figure 5a Shown are the growth curves of H9N2 virus on MDCK (wild-type MDCK cell line in the figure) and MDCK-homoTMEM135 cells;
[0030] Figure 5b Shown are the growth curves of H1N1 (PR8) virus on MDCK (wild-type MDCK cell line in the figure) and MDCK-homoTMEM135 cells;
[0031] Figure 5c The TCID of H9N2 virus on MDCK (wild-type MDCK cell line in the figure) and MDCK-homoTMEM135 cells at different time points are shown. 50 ;
[0032] Figure 5d The TCID of H1N1 (PR8) virus on MDCK (wild-type MDCK cell line in the figure) and MDCK-homoTMEM135 cells at different time points are shown. 50 . DETAILED DESCRIPTION
[0033] To make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described in detail below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other implementation methods obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.
[0034] The above technical solution is described in detail below in conjunction with specific embodiments.
[0035] In the following examples, the plasmid pxPAX2 was purchased from addgene, the pMD2G plasmid was purchased from addgene, and the DH5α competent cells were provided by Tiangen.
[0036] Example 1 Amplification of human TMEM135 gene and construction of stable expression vector
[0037] The specific operations are as follows:
[0038] 1. Extract RNA from A549 cells
[0039] Use Yisheng Cell Total RNA Extraction Kit (Cat. No.: 19221ES50) and follow the product instructions. The steps are as follows:
[0040] (1) Collect the cell sample using lysis buffer LB and collect the lysate into a 1.5 mL RNase-free EP tube.
[0041] (2) The cell lysate was transferred to a DNA cleanup column and centrifuged at 13,000 rpm for 1 min at 4°C to separate RNA, and the filtrate containing RNA was collected.
[0042] (3) Add binding buffer BD in a 1:1 ratio according to the volume of the filtrate and mix gently by pipetting immediately to ensure sufficient reaction.
[0043] (4) Transfer the above mixed solution to a new RNA adsorption column and centrifuge at 13,000 rpm for 30 seconds at 4°C to remove impurities in the filtrate.
[0044] (5) Add 700 μL of deproteinized solution PL to the RNA adsorption column, let it stand at room temperature for 30 seconds, centrifuge at 13,000 rpm for 30 seconds at 4°C, and discard the filtrate.
[0045] (6) Add 600 μL of washing solution W, centrifuge at 13,000 rpm at 4°C for 30 s, and discard the filtrate.
[0046] (7) Place the RNA adsorption column back into the 2 mL collection tube and centrifuge at 13,000 rpm at 4°C for 2 min to completely remove the remaining rinse solution W.
[0047] (8) Transfer the RNA adsorption column to a new 1.5 mL RNase-free centrifuge tube. Add 30-50 μL of RNase-free water preheated to 65°C to the center of the membrane and let stand at room temperature for 1 min. Centrifuge at 13,000 rpm at 4°C for 1 min and collect the filtrate to obtain the RNA sample.
[0048] (9) Use the Yisheng Reverse Transcription Kit (Cat. No.: 11123ES60) and follow the product instructions as follows:
[0049] Reagent name Dosage RNA 1-5 μg DNase removal 3μL RNase-free water To15μL
[0050] Incubate at 42°C for 2 min.
[0051] Reagent name Dosage RNA reaction solution from the previous step 15μL Premixed reverse transcriptase 5μL
[0052] First at 55℃, 15min; then at 85℃, 5s.
[0053] 2. Design of primers for human TMEM135 gene
[0054] Primers were designed based on the sequence of the human TMEM135 gene (gene ID: 65084) predicted in GenBank:
[0055] F (SEQ ID No. 2): ttcaggtgtcgtgaagcggccgcatggcggccctcagcaagtc (endoinuclease: NotI)
[0056] R (SEQ ID No. 3): gttaggggggggggtctagatcaggaaaactctgtgggcaactctgg (endonuclease: XbaI)
[0057] 3. Amplify the human TMEM135 gene and purify it by gel recovery; the PCR system is as follows:
[0058]
[0059]
[0060] The PCR program is as follows:
[0061]
[0062] After 1% agarose gel electrophoresis, the results were as follows Figure 1The obtained human TMEM135 gene sequence is shown in SEQ ID No.1.
[0063] SEQ ID No.1:
[0064]
[0065] 4. Connect and transform
[0066] The connection system is as follows:
[0067] name Dosage DNA [0.04×number of base pairs of insert]ng Vector fragment after Phage plasmid digestion [0.02×number of cloning vector base pairs]ng Homologous recombinase Exnase II 2μl 5×CEII buffer 4μl <![CDATA[ddH2O]]> to20μl
[0068] The conversion steps are as follows:
[0069] (1) Add the ligation product to 50 μL of DH5α competent cells and incubate on ice for 30 min.
[0070] (2) heat shock at 42°C for 45 seconds;
[0071] (3) Add 700 μL LB culture medium and culture at 37°C, 200 rpm for 1 h.
[0072] (4) Coating the board.
[0073] 5. Pick bacteria to extract plasmid phage-TMEM135, that is, construct and obtain the stable expression vector.
[0074] Example 2 Packaging of Lentivirus
[0075] The stable expression vector, pxPAX2 and pMD2G plasmids were combined into a three-plasmid system, which was co-transfected into 293T cells. After 48 hours, the supernatant was collected and centrifuged at 4000 rpm for 5 minutes to obtain packaged lentivirus.
[0076] The specific composition of the three-plasmid system is as shown in the following table. The three-plasmid system is obtained by mixing the reagents in tube A and the reagents in tube B.
[0077]
[0078] Example 3 Lentivirus-infected cell lines
[0079] The specific operations are as follows:
[0080] 1. Plate MDCK cells in a 6-well cell culture plate. When the cell density reaches about 80%, mix serum-free DMEM medium and lentivirus concentrated solution at a ratio of 1:1. Each well contains 2 mL of the lentivirus mixture and 2 μL of polybrene.
[0081] 2. Puromycin was added 12 hours after infection (antibiotic selection). After two screenings, the obtained cells were the MDCK cell line expressing the human TMEM135 gene (MDCK-homoTMEM135 cells). One part was expanded and frozen, and the other part was spread onto a 96-well plate after limiting dilution. Single subclone cells were selected and expanded.
[0082] The obtained MDCK cell line with the human TMEM135 gene (MDCK-homoTMEM135 cells) was deposited in the China Center for Type Culture Collection on August 14, 2024, and classified and named: Canine Kidney Cell MDCK-homoTMEM135, with the collection number CCTCC NO: C2024260.
[0083] Example 4 Identification
[0084] 1. Western Blot Identification
[0085] (1) The single subclone cells selected in step 2 of Example 3 were inoculated into a 6-well plate. After the cells were fully grown for 24 hours, the cells were lysed with 200 μL of 2× lysis buffer and placed in a centrifuge tube.
[0086] (2) The sample was boiled at 100°C for 10 min.
[0087] (3) Gel running: prepare 10% PAGE protein gel, add samples, and run at 80 V for 120 min.
[0088] (4) Transfer: Carefully remove the SDS-PAGE gel from the glass plate and place 4 layers of filter paper, PVDF membrane, gel layer, and 4 layers of filter paper in order from positive to negative. Carefully remove the bubbles in each layer and move it into the electrotransfer device. Pour in the cooled transfer buffer (Tris-glycine-methanol buffer) and place the electrophoresis tank in an ice box. Transfer the membrane at 250 mA for 95 min.
[0089] (5) Blocking: Prepare 10% skimmed milk powder blocking solution and block on a shaker at room temperature for 1 hour.
[0090] (6) Primary antibody incubation: Prepare 5% BSA solution and dilute the primary antibody (homoTMEM135, rabbit antibody, abcam catalog number: ab222237) at 1:1000, and block overnight at 4°C on a shaker. Rinse: Rinse the PVDF membrane three times with TBST solution, 10 minutes each time.
[0091] (7) Secondary antibody incubation: Use TBST to dilute the corresponding secondary antibody (rabbit secondary antibody, abclonal catalog number: AS014) at 1:10000, place the PVDF membrane in the secondary antibody, and incubate on a shaker at room temperature for 1 hour. Rinse: Use TBST solution to rinse the PVDF membrane 3 times, 10 minutes each time.
[0092] (8) Chemiluminescence: Mix the chemiluminescence developer in a 1:1 ratio under light protection, rinse the membrane several times, and then put it into the chemiluminescence developer to detect the results. Figure 2 After subcloning, cells with high TMEM135 gene expression were cultured and preserved.
[0093] 2. qPCR detection of the stability of TMEM135 gene expression in cell lines
[0094] The cells constructed in step 3 were frozen and then revived, and the passage counting was started. RNA of the cells was extracted at the 0th, 10th, 20th, and 30th generations. 1 μg was quantitatively reverse transcribed and then tested by qPCR. Figure 3 As shown, the TMEM135 gene can be stably inherited during cell passaging, indicating that an MDCK cell line stably expressing the human TMEM135 gene was successfully constructed.
[0095] 3. Filipin staining to detect intracellular cholesterol transport
[0096] (1) The cells in the 6-well plate were treated with cholesterol-depleted culture medium (DMEM, 5% low-density lipoprotein-deficient serum, 1 mM lovastatin, 1.5% methyl-β-cyclodextrin, 10 mM mevalonic acid) and then washed twice with sterile 1× PBS.
[0097] (2) Add 4% paraformaldehyde to infiltrate the cell slides and fix the cells for 20 minutes.
[0098] (3) Wash the fixed cell slides three times with sterile 1× PBS, add PBS containing 1.5 mg / mL glycine and incubate the cells for 10 min to quench residual paraformaldehyde.
[0099] (4) Wash the fixed cell slides three times with sterile 1× PBS, dilute the stock concentration of 5 mg / mL Philippine stain to a working concentration of 50 μg / mL with PBS containing 10% FBS, and incubate the cell slides at 37°C for 2 h.
[0100] (5) The sample was mounted on a glass slide, and after the mounting medium solidified, the intracellular cholesterol Filipin staining was photographed using a fluorescent microscope.
[0101] like Figure 4a and Figure 4b As shown: After MDCK and MDCK-homoTMEM135 cells were treated with cholesterol depletion culture, Filipin staining fluorescence observation revealed that cholesterol fluorescence consumption in MDCK-homoTMEM135 was faster than that in MDCK cells.
[0102] 4. Virus growth curve of IAV (H9N2, H1N1 PR8) viruses in MDCK and MDCK-homoTMEM135 cells.
[0103] The cells obtained in step (8) of step 1 were 6Inoculate in 6-well plates, and when the cells grow to 70%, digest one well of cells for counting, and calculate 0.01 MOI to infect H9N2 and H1N1 PR8 respectively. Collect supernatants at 24h, 48h, and 72h after infection and use them to detect TCID 50 .
[0104] like Figure 5a-5d Shown: TCID of IAV virus on MDCK-homoTMEM135 cells 50 The titer was higher than that on MDCK cells.
[0105] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. A MDCK cell line stably expressing the human TMEM135 gene, characterized in that: The cell line was named as canine kidney cell MDCK-homoTMEM135 and deposited in China Center for Type Culture Collection. Its culture collection number is CCTCC NO: C2024260.
2. The MDCK cell line stably expressing the human TMEM135 gene according to claim 1, characterized in that: The nucleotide sequence of the human TMEM135 gene is shown in SEQ ID No.
1.
3. Use of the MDCK cell line stably expressing the human TMEM135 gene according to any one of claims 1-2 in the proliferation of influenza A virus.
4. The method for constructing an MDCK cell line stably expressing the human TMEM135 gene according to any one of claims 1-2, characterized in that: The steps include: (A) Amplify the human TMEM135 gene and construct a stable expression vector; (B) co-transfecting the stable expression vector described in step (A) with pxPAX2 and pMD2G plasmids into 293T cells, and incubating to produce packaged lentivirus; (C) After infecting MDCK cells with the packaged lentivirus, puromycin drug screening was performed and culture was expanded to obtain the MDCK cell line stably expressing the human TMEM135 gene.
5. The construction method according to claim 4, characterized in that: In step (A), the primer sequences for amplifying the human TMEM135 gene are shown in SEQ ID No. 2 and SEQ ID No.
3.
6. The construction method according to claim 4, characterized in that: In step (A), the construction of the stable expression vector is specifically performed as follows: The amplified human TMEM135 gene was connected to the vector fragment, and the resulting connection product was added to DH5α competent cells. After heat shock, it was added to the culture medium for culture, and monoclonal colonies were selected and plasmids were extracted.
7. The construction method according to claim 6, characterized in that: The vector fragment is a vector fragment obtained after Phage plasmid digestion.
8. The construction method according to claim 6, characterized in that: The heat shock is performed at 40-45° C. for 35-45 seconds; and the culture medium is LB culture medium.
